Cyclacel Pharmaceuticals Company Executives
| CYCCP Preferred Stock | USD 9.24 1.41 18.01% |
Cyclacel Pharmaceuticals employs about 14 people. The company is managed by 5 executives with a total tenure of roughly 35 years, averaging almost 7.0 years of service per executive, having 2.8 employees per reported executive. Discussion of Cyclacel Pharmaceuticals' management performance can provide insight into the enterprise performance.
| Spiro Rombotis CEO CEO and President and Executive Director |
Cyclacel |
Cyclacel Pharmaceuticals Management Team Effectiveness
The company has return on total asset (ROA) of (0.4167) % which means that it has lost $0.4167 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.6014) %, meaning that it generated substantial loss on money invested by shareholders. Cyclacel Pharmaceuticals' management efficiency ratios could be used to measure how well Cyclacel Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Cyclacel Pharmaceuticals Workforce Comparison
Cyclacel Pharmaceuticals is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 1,581. Cyclacel Pharmaceuticals maintains roughly 14.0 in number of employees contributing less than 1% to equities under Health Care industry.
Cyclacel Pharmaceuticals Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Cyclacel Pharmaceuticals Price Series Summation is a cross summation of Cyclacel Pharmaceuticals price series and its benchmark/peer.
Cyclacel Pharmaceuticals Notable Stakeholders
A Cyclacel Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Cyclacel Pharmaceuticals often face trade-offs trying to please all of them. Cyclacel Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Cyclacel Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Spiro Rombotis | CEO and President and Executive Director | Profile | |
| Paul McBarron | COO, CFO, Principal Accounting Officer, Executive VP of Fin. and Admin., Secretary and Executive Director | Profile | |
| Gill Christie | Director HR | Profile | |
| Mark MD | VP Officer | Profile | |
| Robert Westwood | Head Devel | Profile |
About Cyclacel Pharmaceuticals Management Performance
The success or failure of an entity such as Cyclacel Pharmaceuticals often depends on how effective the management is. Cyclacel Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Cyclacel management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Cyclacel management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey. Cyclacel Pharmaceuti operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange.
Cyclacel Pharmaceuticals Workforce Analysis
Traditionally, organizations such as Cyclacel Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Cyclacel Pharmaceuticals within its industry.Cyclacel Pharmaceuticals Manpower Efficiency
Return on Cyclacel Pharmaceuticals Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 1.3M | |
| Net Loss Per Executive | 3.8M |
Additional Tools for Cyclacel Preferred Stock Analysis
When running Cyclacel Pharmaceuticals' price analysis, check to measure Cyclacel Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cyclacel Pharmaceuticals is operating at the current time. Most of Cyclacel Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Cyclacel Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cyclacel Pharmaceuticals' price. Additionally, you may evaluate how the addition of Cyclacel Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.